VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has provided an update on its strategy to implement U.S. Food and Drug Administration (FDA)-aligned New Approach Methodologies (NAMs) across its preclinical research and development programs. The company said the approach could accelerate clinical advancement, reduce development costs and timelines, and significantly reduce animal testing. This move is important because it aligns with global regulatory shifts toward more human-relevant testing methods, potentially setting a precedent for the biotechnology industry and improving the efficiency of drug development.
VERAXA has built a panel of NAMs to characterize and de-risk its pipeline of BiTAC-based T cell engagers, antibody-drug conjugates, and bispecific antibody-drug conjugates. According to the company, its lead BiTAC-TCE and bsADC candidates were evaluated using an ex vivo panel of 10 low-passage patient-derived xenograft models of non-small cell lung cancer. This panel required about 10 mice in total, compared with an estimated 200 or more for comparable in vivo efficacy studies. Across the panel, the combined BiTAC consistently induced potent T cell-mediated killing, supporting the company’s dual-targeting approach and demonstrating how its NAM strategy can reduce animal use and preclinical cycle time without compromising clinical relevance.
The implications of this announcement extend beyond animal welfare. By reducing reliance on animal testing, VERAXA may be able to bring therapies to patients faster and at lower cost, as preclinical studies can be completed more quickly and with fewer resources. Moreover, the use of patient-derived xenograft models may provide more clinically relevant data, potentially increasing the likelihood of success in later-stage trials. This approach could also help the company navigate an evolving regulatory landscape where the FDA and other agencies are increasingly encouraging the adoption of NAMs.
For investors and industry observers, VERAXA’s progress with NAMs signals a commitment to innovation and efficiency. The company’s ability to de-risk its pipeline using fewer animals and shorter timelines could translate into a competitive advantage. As the biotechnology sector faces pressure to improve productivity and reduce costs, VERAXA’s strategy may serve as a model for others. The full press release is available at https://ibn.fm/9YRJw, and the latest news and updates relating to VRXA can be found at https://ibn.fm/VRXA.
VERAXA Biotech AG is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL). As VERAXA continues to advance its pipeline, its adoption of NAMs could influence broader industry practices and regulatory acceptance. For more details, see the original release on www.newmediawire.com.
